0

Amlexanox

INQUIRY Add to cart
For Research Use Only | Not For Clinical Use
CATAP68302578
CAS68302-57-8
Structure
MDL NumberMFCD00864790
Molecular Weight298.29
InChI KeySGRYPYWGNKJSDL-UHFFFAOYSA-N
Description≥98% (HPLC)
SolubilityDMSO: 10 mg/mL at warmed, clear
Assay≥98% (HPLC)
Colorwhite to beige
Formpowder
Size10MG, 50MG
Storage Conditions−20°C
1

Amlexanox Ameliorates Acetaminophen-Induced Acute Liver Injury by Reducing Oxidative Stress in Mice

Jing Qi, Zixiong Zhou, Chae Woong Lim, Jong-Won Kim, Bumseok Kim

Toxicol Appl Pharmacol. 2019 Dec 15;385:114767.

PMID: 31697998

1

Amlexanox Reversed Non-Alcoholic Fatty Liver Disease Through IKKε Inhibition of Hepatic Stellate Cell

Qian He, Xuan Xia, Kecheng Yao, Jun Zeng, Wei Wang, Qiong Wu, Renmin Tang, Xiulan Zou

Life Sci. 2019 Dec 15;239:117010.

PMID: 31672578

1

An Inhibitor of the Protein Kinases TBK1 and IKK-ɛ Improves Obesity-Related Metabolic Dysfunctions in Mice

Shannon M Reilly, Shian-Huey Chiang, Stuart J Decker, Louise Chang, Maeran Uhm, Martha J Larsen, John R Rubin, Jonathan Mowers, Nicole M White, Irit Hochberg, Michael Downes, Ruth T Yu, Christopher Liddle, etc.

Nat Med. 2013 Mar;19(3):313-21.

PMID: 23396211

1

Current and Upcoming Pharmacotherapy for Non-Alcoholic Fatty Liver Disease

Yaron Rotman, Arun J Sanyal

Gut. 2017 Jan;66(1):180-190.

PMID: 27646933

1

Targeting IRF3 as a YAP Agonist Therapy Against Gastric Cancer

Shi Jiao, Jingmin Guan, Min Chen, Wenjia Wang, Chuanchuan Li, Yugong Wang, Yunfeng Cheng, Zhaocai Zhou

J Exp Med. 2018 Feb 5;215(2):699-718.

PMID: 29339449

  • Verification code
Contact Us

Send Us a Request

What is your specific need? We will do everything we can to meet your expectations.
Online Inquiry

Inquiry

For any inquiry, question or recommendation, please call: or fill out the following form.

  • Verification code

Head Office

  • Tel:
  • Email:

Follow us on

qrcode